Abstract
Objective To investigate p16 and death-associated protein kinase (DAPK) promoter methylation in the blood serum of patients with non-invasive urinary bladder cancer. Methods p16 and DAPK promoter methylations in blood serum of patients with non-invasive urinary bladder cancer (experimental group, n=25) and healthy volunteers (control group, n=25) were detected by methylation specific polymerease chain reaction (MSP), and their clinical implications were analyzed. Results The methylation rate of p16 in experimental group was 52% (13/25), higher than 24% (6/25) in control group(χ2=4.160, P=0.041); The methylation rate of DAPK in experimental group was 60% (15/25), higher than 32% (8/25) in control group (χ2=3.945, P=0.047). Both of them had statistically significant difference. The methylation rate of p16 and DAPK was not correlated with smoking (χ2=0.187, P=0.665; χ2=0.109, P=0.741), age (χ2=0.000, P=0.991; χ2=0.038, P=0.845), gender (χ2=0.746, P=0.382; χ2=1.288, P=0.256) or the grade of tumor (P=1.000; P=1.000). Conclusion p16 and DAPK promoter methylations are closely related to non-invasive urinary bladder cancer. Key words: Bladder cancer; p16; Death-associated protein kinase; Methylation
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call